中外医疗
中外醫療
중외의료
CHINA FOREIGN MEDICAL TREATMENT
2015年
13期
142-143
,共2页
系统性红斑狼疮%利妥昔单抗%小剂量%安全性
繫統性紅斑狼瘡%利妥昔單抗%小劑量%安全性
계통성홍반랑창%리타석단항%소제량%안전성
Systemic lupus erythematosus%Rituximab%Small doses%Security
目的：探讨系统性红斑狼疮应用小剂量利妥昔单抗治疗的疗效。方法将该院收治的系统性红斑狼疮患者64例随机分为两组各32例，观察组给予小剂量利妥昔单抗治疗，参照组应用环磷酰胺治疗，对比其疗效。结果与参照组比较，观察组治疗后2周的外周血B细胞数量及随访终点BILAG与SLEDAI评分均显著较低(P<0.05)；且观察组的总有效率(90.63%)显著高于参照组(68.75%)，差异有统计学意义(P<0.05)。结论与环磷酰胺比较，系统性红斑狼疮应用小剂量利妥昔单抗治疗的疗效更为显著，值得推广。
目的：探討繫統性紅斑狼瘡應用小劑量利妥昔單抗治療的療效。方法將該院收治的繫統性紅斑狼瘡患者64例隨機分為兩組各32例，觀察組給予小劑量利妥昔單抗治療，參照組應用環燐酰胺治療，對比其療效。結果與參照組比較，觀察組治療後2週的外週血B細胞數量及隨訪終點BILAG與SLEDAI評分均顯著較低(P<0.05)；且觀察組的總有效率(90.63%)顯著高于參照組(68.75%)，差異有統計學意義(P<0.05)。結論與環燐酰胺比較，繫統性紅斑狼瘡應用小劑量利妥昔單抗治療的療效更為顯著，值得推廣。
목적：탐토계통성홍반랑창응용소제량리타석단항치료적료효。방법장해원수치적계통성홍반랑창환자64례수궤분위량조각32례，관찰조급여소제량리타석단항치료，삼조조응용배린선알치료，대비기료효。결과여삼조조비교，관찰조치료후2주적외주혈B세포수량급수방종점BILAG여SLEDAI평분균현저교저(P<0.05)；차관찰조적총유효솔(90.63%)현저고우삼조조(68.75%)，차이유통계학의의(P<0.05)。결론여배린선알비교，계통성홍반랑창응용소제량리타석단항치료적료효경위현저，치득추엄。
Objective To investigate the effect of low-dose systemic lupus erythematosus rituximab treatment.Methods Patients with systemic lupus erythematosus our hospital 64 cases were randomly divided into two groups of 32 cases, observation group were given small doses of rituximab treatment, referring to the use of cyclophosphamide treatment group, compared to its efficacy. Results Compared with the reference group, the observation group after two weeks of treatment the number of peripheral blood B cells and follow-up end BILAG and SLEDAI scores were significantly lower (P<0.05),and the total efficiency of the observation group (90.63%) was significantly higher than the reference group (68.75%), the difference was statistically significant (P<0.05). Conclusion Compared with cyclophosphamide, the efficacy of low-dose systemic lupus erythematosus rituximab therapy is more significant, worthy of promotion.
